Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

VolitionRx Limited raises around US$12.8mln from share offer

Cancer diagnostics group VolitionRx Limited has raised around US$12.8mln from its share placing, which will be used to further the business, including for clinical studies and product commercialisation.
VolitionRx Limited raises around US$12.8mln from share offer
Last week the group priced its US$12.25mln placing at US$3.25 per share, around a 10% discount to the market price at the time...

Cancer diagnostics group VolitionRx Limited (NYSE:VNRX) has raised around US$12.8mln from its share placing, which will be used to advance the business, including for clinical studies and product commercialisation.

Last week the group priced its US$12.25mln placing at US$3.25 per share, around a 10% discount to the market price at the time.

The firm issued around 3.7mln shares and a further 565,384 additional stock as the over-allotment option was taken in full.

"VolitionRx intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital and other general corporate purposes," it said.

The company has developed the NuQ diagnostic test that measures nucleosomes in the bloodstream – an indication that cancer is present.

Results have been encouraging in trials so far for colorectal, lung and prostate cancer with detection rates of over 90%.

The company is currently going through the approval process for a European CE mark and expects a commercial launch of the test this year for clinical use in Europe, with meaningful sales expected to begin in 2017.

Giles_55af4ddca6481.jpg


Register here to be notified of future VNRX Company articles
View full VNRX profile

VolitionRx Timeline

Related Articles

blood_56ceb82789b61.jpg
December 15 2016
The company's nominated adviser said a partnership deal should be signed by the end of 2016
picture of someone with head pain
December 07 2016
Its strategy is to develop cell lines for "off the-shelf" therapies to treat serious conditions
shutterstock_255595165.jpg
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use